New Indication: Polatuzumab in Untreated DLBCL
Study
Double-blind Phase III trial
|
Untreated intermediate-risk or high-risk DLBCL
|
Polatuzumab-R-CHP vs R-CHOP
|
Efficacy
2 years PFS: 76.7% vs 70.2% (HR:0.73 95% Cl 0.57-0.95 p=0.02)
|
2 years OS: 88.7% vs 88.6% (HR:0.94 95% Cl 0.65-1.37 p=0.75)
|
Safety
Any grades AEs: All 97.9% vs 98.4%,
|
Grade >=3 AEs: 60.7% vs 59.8%
|
Serious AEs:34.0% vs 30.6%
|
Grade 5 AEs: 3.0% vs 2.3%
|
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022